ASKB589 + capecitabine + oxaliplatin + sintilimab + tislelizumab

ASKB589 + capecitabine + oxaliplatin + sintilimab + tislelizumab is an investigational combination regimen consisting of five active ingredients, including a novel agent ASKB589 developed as a Galectin-3 monoclonal antibody, two chemotherapeutic agents (capecitabine and oxaliplatin), and two PD-1 immune checkpoint inhibitors (sintilimab and tislelizumab). The regimen is under evaluation for the treatment of advanced malignancies, including gastric, gastroesophageal junction, and colorectal cancers. - **ASKB589** is a monoclonal antibody targeting Galectin-3, an immunosuppressive protein involved in tumor progression and resistance to immune therapies. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU) that inhibits DNA synthesis in rapidly dividing cancer cells[1][3][5]. - **Oxaliplatin** is a platinum-based alkylating agent that causes DNA crosslinking and apoptosis in cancer cells[1][3][5]. - **Sintilimab** and **tislelizumab** are humanized monoclonal antibodies targeting PD-1, leading to enhanced T cell-mediated anti-tumor immunity[6]. This combination leverages cytotoxic chemotherapy with dual immune checkpoint blockade and Galectin-3 inhibition to maximize anti-tumor response.